PLX Share Price

Open 0.30 Change Price %
High 0.31 1 Day 0.00 0.00
Low 0.29 1 Week -0.01 -3.23
Close 0.30 1 Month -0.16 -34.78
Volume 1090181 1 Year -0.59 -66.29
52 Week High 1.05
52 Week Low 0.27
PLX Important Levels
Resistance 2 0.32
Resistance 1 0.31
Pivot 0.30
Support 1 0.29
Support 2 0.28
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
NAK 1.75 -8.38%
NAK 1.75 -8.38%
RBY 0.03 -70.00%
PBTH 8.23 0.37%
NGD 3.80 -2.81%
NGD 3.80 -2.81%
SYRG 9.82 -0.30%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
CPHI 0.29 52.63%
IGC 0.33 37.50%
IGC 0.33 37.50%
IGC 0.33 37.50%
MBA 0.20 25.00%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
INV 0.14 -17.65%
More..

Protalix BioTherapeutics, Inc. (AMEX: PLX)

PLX Technical Analysis 5
As on 9th Dec 2016 PLX Share Price closed @ 0.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.70 & Strong Sell for SHORT-TERM with Stoploss of 0.49 we also expect STOCK to react on Following IMPORTANT LEVELS.
PLX Target for December
1st Target up-side 0.69
2nd Target up-side 0.78
3rd Target up-side 0.87
1st Target down-side 0.43
2nd Target down-side 0.34
3rd Target down-side 0.25
PLX Other Details
Segment EQ
Market Capital 441232352.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.protalix.com
PLX Address
PLX
2 Snunit Street
Science Park
Carmiel, 21000
Israel
Phone: 972 4 988 9488
Fax: 972 4 988 9489
Interactive Technical Analysis Chart Protalix BioTherapeutics, Inc. ( PLX AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Protalix BioTherapeutics, Inc.
PLX Business Profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant glucocerebrosidase enzyme produced and encapsulated within carrot cells; and PRX-106, an oral antiTNF, a plant cell expressed recombinant fusion protein combined of the binding domain of the human TNF receptor and an antibody portion, which is being developed for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, colitis, Crohn’s disease, psoriasis, and other autoimmune and inflammatory disorders. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and PRX-107, a proprietary plant cell recombinant human Alpha1-antitrypsin and others. The company has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.